Cantor Fitzgerald analyst Elemer Piros says PolarityTE’s presentation yesterday highlighted differentiated case studies in which SkinTE was an effective treatment in restoring the regenerative properties of skin. In one case study, SkinTE was applied to correct a previous failed split-thickness skin graft, Piros tells investors in a research note. Although early, preclinical work shows a potential for SkinTE to address certain genetic diseases, contends the analyst. He believes upcoming data presentations at the Symposium on Advanced Wound Care Conference on May 7-11 is an “important upcoming catalyst.” Piros thinks PolarityTE “can revolutionize the field of regenerative medicine.” He reiterates an Overweight rating on the shares with a $65 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.